Type 2 Diabetes and Thiazide Diuretics

Current Diabetes Reports
André J Scheen


In patients with prediabetes or type 2 diabetes, the use of thiazides as antihypertensive agents has been challenged because associated metabolic adverse events, including new-onset diabetes. These metabolic disturbances are less marked with low-dose thiazides and, in most but not all studies, with thiazide-like diuretics (chlorthalidone, indapamide) than with thiazide-type diuretics (hydrochlorothiazide). In post hoc analyses of subgroups of patients with hypertension and type 2 diabetes, thiazides resulted in a significant reduction in cardiovascular events, all-cause mortality, and hospitalization for heart failure compared to placebo and generally were shown to be non-inferior to other antihypertensive agents. Benefits attributed to thiazide diuretics in terms of cardiovascular event reduction outweigh the risk of worsening glucose control in type 2 diabetes and of new-onset diabetes in non-diabetic patients. Thiazides still play a key role in the management of patients with type 2 diabetes and hypertension.


Jul 1, 1991·Archives of Internal Medicine·J H WarramA S Krolewski
Feb 15, 1993·Annals of Internal Medicine·J H GurwitzJ Avorn
Sep 30, 1996·The American Journal of Medicine·M R WeirW B Applegate
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Mar 26, 2003·Hypertension·Carl Erik MogensenUNKNOWN Preterax in Albuminuria Regression (PREMIER) Study Group
May 22, 2003·JAMA : the Journal of the American Medical Association·Bruce M PsatyNoel S Weiss
Jul 25, 2003·American Journal of Hypertension·Shi-Wen KuoWei-Cheng Lian
Aug 20, 2003·Diabetic Medicine : a Journal of the British Diabetic Association·H KrumR E Gilbert
Jul 9, 2004·JAMA : the Journal of the American Medical Association·Bruce M PsatyCurt D Furberg
Sep 15, 2004·The Journal of Clinical Hypertension·Doemnic A Sica
Dec 28, 2004·The American Journal of Cardiology·John B KostisUNKNOWN SHEP Collaborative Research Group
Dec 7, 2005·Journal of Hypertension·Giuseppe ManciaAlberto Zanchetti
Dec 31, 2005·Journal of Cardiovascular Pharmacology and Therapeutics·Giulia Dell'OmoRoberto Pedrinelli
Mar 28, 2006·Journal of the American Society of Nephrology : JASN·Antonio Salvetti, Lorenzo Ghiadoni
Jan 3, 2007·American Journal of Hypertension·Juan Garcia PuigRoland Asmar
Apr 11, 2007·Current Opinion in Nephrology and Hypertension·Joshua I BarzilayBarry R Davis
Apr 2, 2008·The New England Journal of Medicine·Nigel S BeckettUNKNOWN HYVET Study Group
Apr 26, 2008·American Journal of Hypertension·Michael H Alderman
Aug 23, 2008·BMJ : British Medical Journal·Bruce ArrollC Raina Elley
Sep 23, 2008·Journal of Hypertension·Josep RedonUNKNOWN Scientific Council of the European Society of Hypertension
Nov 21, 2008·Expert Review of Cardiovascular Therapy·Rhonda M Cooper-DeHoff
May 27, 2010·European Heart Journal·Hiddo J Lambers HeerspinkUNKNOWN ADVANCE Collaborative Group
Jul 14, 2010·Journal of the American College of Cardiology·Michael A WeberUNKNOWN ACCOMPLISH Investigators
Oct 30, 2010·Journal of the American College of Cardiology·Jacob C JentzerAdrian F Hernandez
May 6, 2011·Diabetes Care·Ehud GrossmanGianpaolo Reboldi
Sep 8, 2011·The Journal of Clinical Hypertension·Domenic A SicaLee Hamm
Dec 7, 2011·The Journal of Clinical Hypertension·Clive Rosendorff
Dec 21, 2011·Nature Reviews. Nephrology·Domenic A Sica
Aug 14, 2012·Lancet·Ele Ferrannini, William C Cushman
May 15, 2013·Diabetes, Obesity & Metabolism·H J Lambers HeerspinkJ List
Jun 27, 2013·Journal of the American Society of Hypertension : JASH·Bertrand N Mukete, Clive Rosendorff
Jul 11, 2013·Diabetology & Metabolic Syndrome·Angela L PriceLidia S Szczepaniak
Nov 19, 2013·Journal of Cardiovascular Pharmacology and Therapeutics·George C RoushMichael E Ernst

❮ Previous
Next ❯


Nov 22, 2018·Expert Opinion on Pharmacotherapy·Pierre Delanaye, André J Scheen
Dec 26, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Mónica Ríos-SilvaMiguel Huerta
Jun 23, 2019·Current Cardiology Reports·André J Scheen
Dec 16, 2020·Diabetes, Obesity & Metabolism·David S H Bell, Edison Goncalves
Mar 26, 2020·Current Diabetes Reviews·Moein AlaAhmad Reza Dehpour

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

© 2021 Meta ULC. All rights reserved